Empliciti
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Empliciti (elotuzumab; Bristol-Myers Squibb/AbbVie) is a monoclonal antibody that targets the signaling lymphocytic activation molecule family, member 7 (SLAMF7), also called CS1. This cell-surface glycoprotein is expressed in high levels on multiple myeloma (MM) cells and normal plasma cells. It is also expressed on natural killer (NK) cells where it functions as an activating receptor. Empliciti induces MM cell death by direct activation of NK cells and through antibody-dependent NK cell-mediated cytotoxicity.
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Empliciti : Multiple myeloma
LIST OF FIGURES
13 Figure 1: Empliciti for multiple myeloma – SWOT analysis
14 Figure 2: Datamonitor Healthcare’s drug assessment summary of Empliciti for multiple myeloma
15 Figure 3: Datamonitor Healthcare’s drug assessment summary of Empliciti for multiple myeloma
17 Figure 4: Empliciti sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: Empliciti drug profile
7 Table 2: Empliciti pivotal trial data in multiple myeloma
9 Table 3: Empliciti early-phase trial data in multiple myeloma
12 Table 4: Empliciti ongoing late-phase clinical trials in multiple myeloma
18 Table 5: Empliciti sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
20 Table 6: Patients treated with Empliciti across the US, Japan, and five major EU markets, by country, 2017–26
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Velcade 
Sign up to the